Ipsen Manufacturing
Ipsen is a biotechnological group aiming to become a leader in specialty healthcare solutions for debilitating diseases. Its strategy is supported by three franchises, neurology, endocrinology and urology-oncology.
Ipsen has a growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumours and a presence in primary care.
The group has more than 4,500 employees spread across R&D and manufacturing sites located in China, France, Ireland, the UK and the US.
Financial Data
-
31st Dec 18 Source: CRO
- €143.5 million turnover
-
€121.8 million
profit - 141 employees
-
31st Dec 17 Source: CRO
- €122.2 million turnover
-
€104 million
profit - 125 employees
- 6 more years available »
Ranking
By Turnover
(€143.5 million)- 390th in Top Companies
- 41st in Health
- 41st in Pharma
- 59th in Manufacturing
By Employees
(141)- 653rd in Top Companies
- 78th in Health
- 59th in Pharma
- 99th in Manufacturing
- 141
- €143.5 million
Employees
- James Byrne General Manager
Latest News
- Dec 03 Twitter ruling due as data watchdog rues decision process
- Dec 03 Fire expert warned about flammable material three years before Grenfell fire
- Dec 03 European shares end flat as Brext talks enter endgame
- Dec 03 European shares end flat as Brexit talks enter endgame
- Dec 03 Dunnes secures injunction preventing Mr Price selling food products